Tvardi Posts Q2 Loss, Extends Cash Runway to Q3 2027, and Selects UC for TTI-109
TVRD sits 21% above its 52-week low of $1.5 on light trading volume (0.1× avg).
Summary
Tvardi reported Q2 2026 results with a $6.5M net loss and $15.8M cash, extending runway to Q3 2027. The company selected ulcerative colitis as the first indication for TTI-109.
Key Events · Earnings and Guidance · TVRD
-
Q2 Net Loss of $6.5M
Net loss for Q2 2026 was $6.5 million, compared to net income of $4.2 million in Q2 2025, which included a $12.7 million non-cash gain from convertible note fair value changes.
-
Cash Runway Extended to Q3 2027
Cash, cash equivalents, and short-term investments totaled $15.8 million as of June 30, 2026, down from $30.8 million at year-end 2025. Management expects this to fund operations through the HCC topline readout into Q3 2027.
-
UC Selected as First Indication for TTI-109
Tvardi selected ulcerative colitis as the initial disease indication for TTI-109, citing STAT3's role as a convergent node in UC pathogenesis and a U.S. addressable market of approximately $3 billion.
-
KOL Webinar on August 19
The company will host a KOL webinar featuring Dr. Randy Longman on August 19, 2026, to discuss the clinical potential of TTI-109 in UC.
Analysis · TVRD · Life Sciences
The second quarter brought a net loss of $6.5 million for Tvardi, leaving $15.8 million in cash—enough to fund operations through the HCC topline readout in Q3 2027. Ulcerative colitis was also chosen as the first indication for its next-generation STAT3 inhibitor TTI-109, with a KOL webinar set for August 19. Although the cash balance has fallen from $30.8 million at year-end, the extended runway removes near-term financing risk, and the UC indication provides a clear development path.
At the time of this filing, TVRD was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.6M. The 52-week trading range was $1.50 to $43.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.